Antiphospholipid Syndrome (APS) research hub
6 indexed studies · 4 currently recruiting
- enrolling by invitationPHASE1
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
This study is looking at a new treatment called RAY121 for people with certain immune conditions like lupus-like disorders, skin blistering, or blood problems. It's a long-term follow-up for people who did well in an earlier study, to see how RAY121 works over time and if it continues to help.
Australia · Austria · Bulgaria - recruitingPHASE1
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This study is testing a new medicine, RAY121, for several immune system diseases like Antiphospholipid Syndrome and Behçet's Syndrome. Researchers want to see if RAY121 is safe and how it works in the body. It's an early-stage trial.
United States · Australia · Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP).
This study is testing a new medicine called rilzabrutinib for adults with a blood condition called Immune Thrombocytopenia (ITP). It compares the new medicine to a dummy treatment to see if it can help increase blood platelet counts and improve quality of life.
Hungary · Spain · Italy - recruitingPHASE2, PHASE3
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
This study is looking into a new medicine called efgartigimod for young people aged 12 to 17 with a blood condition called chronic ITP. The aim is to find the best dose to help increase their platelet count and manage their condition.
France · Germany · Italy - authorisedTherapeutic exploratory (Phase II)
Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)
This study looks at a medicine called ianalumab for adults with certain blood conditions (ITP or wAIHA). It wants to see if the medicine continues to work well for those who have used it before, aiming to understand its long-term benefits.
Germany · Czechia · Belgium - recruitingPHASE1, PHASE2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
This study is testing a new medicine called pirtobrutinib for people with Immune Thrombocytopenia (ITP). It aims to see how safe it is, what side effects it might cause, and if it helps improve blood platelet counts.
United States · China · Denmark